Pathogenesis and management issues for non-alcoholic fatty liver disease
about
Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspectiveSignal transductions and nonalcoholic fatty liver: a mini-reviewCardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An updateOxidative stress in obesity: a critical component in human diseasesHistological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis.Fatty liver disease in children: eat now pay later.Inflammatory mediators of hepatic steatosis.Nutrition and exercise in the management of liver cirrhosisHepatoprotective effects of Spirulina maxima in patients with non-alcoholic fatty liver disease: a case seriesThe medical risks of obesity.Development of diet-induced fatty liver disease in the aging mouse is suppressed by brief daily exposure to low-magnitude mechanical signals.Saturated fatty acid induction of endoplasmic reticulum stress and apoptosis in human liver cells via the PERK/ATF4/CHOP signaling pathway.Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India.TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats.Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosisInflammation, oxidative stress, and obesity.6-gingerol protects against nutritional steatohepatitis by regulating key genes related to inflammation and lipid metabolism.Reduction of oxidative stress attenuates lipoapoptosis exacerbated by hypoxia in human hepatocytes.Evaluation of atherosclerotic findings in patients with nonalcoholic fatty liver disease.Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis.Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin?Evaluation of relationship between grading of fatty liver and severity of atherosclerotic finding.Water Soluble Vitamin E Administration in Wistar Rats with Non-alcoholic Fatty Liver Disease.Raised liver enzymes in newly diagnosed Type 2 diabetes are associated with weight and lipids, but not glycaemic control.The prevalence of metabolic risk factors among outpatients with diagnosed nonalcoholic fatty liver disease in Lithuania.Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes.Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitisProbiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidencesLiver dysfunction in Turner's syndrome: prevalence, natural history and effect of exogenous oestrogen.Non alcoholic fatty liver disease and metabolic syndrome.Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms.Signal transduction mechanism of TRB3 in rats with non-alcoholic fatty liver diseaseHypertension and hepatic steatosis.Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?Inflammation and liver.Recent advances in the herbal treatment of non-alcoholic Fatty liver disease.Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs.Probiotics and Nonalcoholic Fatty liver Disease.Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment.Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease.
P2860
Q26863476-BFAD161E-A1DA-417A-B523-AE6DEA2A0AD6Q26991757-3E93645C-CE9A-4216-9CC5-43954339E7DAQ26997059-5A83D1B6-BE9C-40FC-983A-AC517EBDE353Q28082703-00B0BE63-AAC9-4FA2-9DFA-2CCCE3F24418Q33602167-65F70862-8C14-4F94-9711-036DF9CA9124Q33718945-518954D9-4E0B-4CFC-809A-7BDD4DE66141Q33734136-CB4533C3-7B3A-41BE-9329-3614304AE598Q33780141-352310B8-0D29-4B33-ACA9-DE301D367034Q33816223-AFB58E41-F38F-459F-850A-BDCEDEB3DE24Q33888248-3F62B979-D040-4686-8FA6-7AF6D76D4084Q34087887-8DA96345-FEFD-46F5-8889-3DB059374BC0Q34128069-BA9ED733-84F1-4841-B0B0-D5DE318D2AC7Q34550839-C815B1FC-6E63-4640-8E47-DA436B3CC3D5Q34721238-A8BDBD34-2D97-4A30-A996-496C80C495F4Q35009517-6A768A07-5B9A-4D87-A044-0985B0BEFA2BQ35048584-788D98EC-5706-47F3-8EE9-9E488DFC96D8Q35131341-0B362076-B92A-4A96-A41D-2BFD200FC8AEQ35139035-BA8B70A3-83D8-48DB-9917-9C92B37FDFA6Q35560585-979B6EBD-01C4-44C5-BB12-E6C17777055AQ35716357-074DEC53-6894-40F3-95E5-A8C83D981E7DQ36105525-C05EDE4F-430A-42A3-AC2F-05D2A7B5E946Q36111640-BB473F8E-4D08-4C8D-8AE8-2E843F079369Q36192489-8F368DDC-AB87-417E-9BC1-8401D0420F16Q36436401-8A066401-9111-49BC-A5EF-08AA1AD23B20Q36577007-6B574F72-8FC6-46A6-BD5C-4265D6257802Q36872035-1A51931C-0FAE-4720-8845-DE3BE625139AQ37025294-DFA7FA1C-1040-44DD-BFD6-065E35C37DFFQ37034650-B58C846A-F276-4802-BB77-A1D0BEBDB668Q37076529-1B3AFEF0-285C-4251-8C15-4A5986DFE6E5Q37078311-8488805A-AC39-4351-BF36-85806D538E95Q37192623-C5CA8BA7-7792-4161-9092-4857FA2C3085Q37198294-4DEAFB2B-A0D5-40BE-ACA5-DF8B917A1FA7Q37258815-9D96B058-1ABD-4766-846B-8E78E392E887Q37313049-DD77756F-F4BF-4529-9A5B-5C4F0B6D4787Q37313768-412743B1-BCCB-4F4D-AF60-20F2EF474422Q37585296-246D258C-1790-46EB-BAEA-2410520DB6D0Q37620806-EF4BCA5A-19C4-49E5-9C2E-2FF5FAF809D5Q37708418-6B219212-6148-4311-ADDC-C8EE6D829C4AQ37847587-3B929347-0542-4FD4-B618-4B0C4A6B7F2AQ37858449-11DDB19A-2327-4E46-9DA1-28C03230FD21
P2860
Pathogenesis and management issues for non-alcoholic fatty liver disease
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pathogenesis and management issues for non-alcoholic fatty liver disease
@ast
Pathogenesis and management issues for non-alcoholic fatty liver disease
@en
type
label
Pathogenesis and management issues for non-alcoholic fatty liver disease
@ast
Pathogenesis and management issues for non-alcoholic fatty liver disease
@en
prefLabel
Pathogenesis and management issues for non-alcoholic fatty liver disease
@ast
Pathogenesis and management issues for non-alcoholic fatty liver disease
@en
P2093
P2860
P356
P1476
Pathogenesis and management issues for non-alcoholic fatty liver disease
@en
P2093
Ivan Lerotić
Lucija Virović Jukić
Marko Duvnjak
Neven Barsić
Vedran Tomasić
Vedran Velagić
P2860
P304
P356
10.3748/WJG.V13.I34.4539
P407
P577
2007-09-01T00:00:00Z